Novel Anti-Inflammatory and Neuroprotective Agents for Parkinsons Disease

Author(s): Li Lu, Fengqiao Li, Xiaomin Wang

Journal Name: CNS & Neurological Disorders - Drug Targets
(Formerly Current Drug Targets - CNS & Neurological Disorders)

Volume 9 , Issue 2 , 2010

Become EABM
Become Reviewer


Parkinsons disease (PD) is a type of motor system disorder that results from the progressive loss of dopaminergic (DAergic) neurons in the substantia nigra (SN) of the midbrain. It is one of the most common neurodegenerative disorders, with an incidence that is second only to Alzheimers disease (AD). Although replacement of dopamine can temporarily alleviate the symptoms of PD patients, it can not prevent the progression of the disease. Increasing evidence has suggested that neuroinflammation significantly contributes to the progress of PD. Therefore, anti-inflammatory therapy could represent a promising neuroprotective intervention with the potential to delay or prevent onset of the disease. This review summarizes several novel potential agents/candidates that might open new avenues for the treatment of PD. In addition to possessing demonstrated anti-inflammatory activities that operate through different molecular mechanisms, these agents exert neuroprotective effects by enhancing the production of neurotrophic factors or interfering with the apoptosis of neurons.

Keywords: Triptolide, minocycline, glatiramer acetate, Parkinson's disease, anti-inflammation

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [232 - 240]
Pages: 9
DOI: 10.2174/187152710791012035
Price: $65

Article Metrics

PDF: 28